Humacyte Inc reports results for the quarter ended March 31 - Earnings Summary

Humacyte

13/05/2025 14:31

Humacyte Inc HUMA.OQ reported quarterly adjusted earnings of 28 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -29 cents.  The mean expectation of six analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -26 cents to -15 cents per share.

Revenue was $517.00 thousand​; analysts expected $760.33 thousand.

Humacyte Inc's reported EPS for the quarter was 28 cents​.

The company reported quarterly net income of $39.14 million.

Humacyte Inc shares had fallen by 22.6% this quarter and lost 73.9% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 20.8% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Humacyte Inc is $8.00

This summary was machine generated from LSEG data May 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.19
0.28
Beat
Dec. 31 2024
-0.25
-0.16
Beat
Sep. 30 2024
-0.25
-0.33
Missed
Jun. 30 2024
-0.24
-0.48
Missed